Global

Massive Bleeding

This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.
This content is intended for use by healthcare professionals.

Coagulation abnormalities can arise from massive bleeding, such as loss, consumption or dilution of coagulation factors, platelets and other blood cells involved in hemostasis.4
Massive bleeding is commonly defined as loss of entire blood volume within 24 hours, or loss of 50% of blood volume within three hours.14

Massive bleeding and coagulopathy may be associated with a number of conditions and procedures such as advanced liver disease, obstetric complications (post-partum hemorrhage), disseminated intravascular coagulation (DIC), major trauma or surgery. It may also be caused by a deficiency in plasma fibrinogen levels. 4-5

CSL Behring products used in the treatment of coagulopathy associated with massive bleeding include: